Given that our data (Supplementary Fig. 3A,B) and a previous report15, both indicate that inhibition of DYRK1B function by AZ-DYRK1B-33 had no clear cytotoxicity in vitro even at high concentration and the topical application of AZ-DYRK1B-33 in mice in vivo did not show any obvious side effects, we believe that this compound is a promising candidate drug for ACD. Here, DYRK1B is linked to granular corneal dystrophy type II.